BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Abviva, Inc. Announces Patent Issuance for Core Technology Used in Mammastatin Serum Assay Diagnostic Test for Breast Cancer


2/22/2008 8:55:08 AM

LOS ANGELES--(BUSINESS WIRE)--Abviva, Inc. (Abviva) (OTCBB:AVVA), a biomedical company engaged in the innovation, development and commercialization of breast cancer diagnostic and therapeutic applications of Mammastatin, announced today that the United States Patent and Trademark Office issued a pivotal patent on the core technology used in the Company’s breast cancer diagnostic test, the Mammastatin Serum Assay (MSA). The patent, titled METHODS AND COMPOSITION FOR DIAGNOSING BREAST CANCER is the most recent of the patents in the Mammastatin IP portfolio to issue to the University of Michigan for breast cancer diagnostic and breast cancer therapeutic uses. “Abviva is the exclusive licensee of the diagnostic uses for Mammastatin in the patent portfolio owned by the University of Michigan and licensed to Abviva,” said Doug Lane, president and chief executive of the company. “Abviva has the exclusive option to license the therapeutic uses of Mammastatin from the University of Michigan to develop one or more breast cancer therapeutic drugs.”

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES